

Gene cloning, sequence analysis, and expression of 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase


PIMCHAI CHAIYEN, DAVID P. BALLOU, AND VINCENT MASSEY*

Department of Biological Chemistry, University of Michigan, Ann Arbor, MI 48109-0606

Contributed by Vincent Massey, May 9, 1997

ABSTRACT The gene encoding 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase (MHPCO; EC 1.14.12.4) was cloned by using an oligonucleotide probe corresponding to the N terminus of the enzyme to screen a DNA library of *Pseudomonas* sp. MA-1. The gene encodes for a protein of 379 amino acid residues corresponding to a molecular mass of 41.7 kDa, the same as that previously estimated for MHPCO. MHPCO was expressed in *Escherichia coli* and found to have the same properties as the native enzyme from *Pseudomonas* sp. MA-1. This study shows that MHPCO is a homotetrameric protein with one flavin adenine dinucleotide bound per subunit. Sequence comparison of the enzyme with other hydroxylases reveals regions that are conserved among aromatic flavoprotein hydroxylases.

2-Methyl-3-hydroxypyridine-5-carboxylic acid oxygenase (MHPCO; EC 1.14.12.4) is a flavin adenine dinucleotide (FAD)-containing enzyme involved in the degradation of vitamin B₆ (pyridoxine) by the soil bacterium *Pseudomonas* sp. MA-1 (P-MA1) (1). Degradation of vitamin B₆ proceeds via an oxidative pathway that is induced when these bacteria are grown on pyridoxine or pyridoxamine as their sole source of carbon and nitrogen (2, 3). The pathway consists of a series of oxidative, hydrolytic, and decarboxylation reactions that convert pyridoxine to metabolites readily assimilated for growth. MHPCO catalyzes an oxygenation reaction and a ring cleavage of its substrate, MHPC, to yield α -(N-acetylamino-methylene)succinic acid as shown in Eq. 1 (1).



Although the reaction catalyzed by MHPCO is formally a dioxygenation, MHPCO belongs to the external aromatic flavoprotein monooxygenase (or aromatic flavoprotein hydroxylase) class (4, 5). The reductive half-reaction (4) shows roles of the aromatic substrate and pyridine nucleotide in the reaction mechanism similar to those found with conventional aromatic flavoprotein hydroxylases, and the oxidative half-reaction (5) involves C(4a)-hydroperoxy-flavin and C(4a)-hydroxy-flavin intermediates, which are common to all other aromatic flavoprotein hydroxylases. Studies of the reaction with a substrate analog, 5-hydroxynicotinic acid, also show that the enzymatic reaction of MHPCO consists of two parts: hydroxylation and a subsequent ring cleavage reaction (5).

Previous studies with MHPCO were unable to firmly establish if the enzyme has a structure of α_4 or $\alpha_2\beta_2$. The stoichiometry of 2 FAD per holoenzyme was reported by Sparrow *et*

al. (1) and Kishore *et al.* (6). Molecular mass of the holoenzyme was determined to be about 166 kDa (1, 6), and each subunit has a size of 43 kDa as shown by SDS/PAGE (6). The subunits of the enzyme appeared to be identical, because they migrate as a single band in SDS/PAGE. It was therefore thought that the enzyme had an α_4 subunit-composition with two FAD bound per tetramer or an $\alpha_2\beta_2$ composition with the α and β subunits being very similar in size. Therefore, we decided to clone and express the enzyme, which would help to clarify the subunit composition and provide information that should be valuable in future structure–function relationship studies.

MATERIALS AND METHODS

Bacterial Strains, Plasmids, and Reagents. P-MA1 and MHPCO were prepared according to ref. 4. P-MA1 genomic DNA was purified by using a DNA purification column (Qiagen). The pGEM-T vector and *Escherichia coli* JM109 were obtained from Promega. The pBluescript II SK(+) was from Stratagene. The pET-11a vector and *E. coli* BL21(DE3) were from Novagen. Restriction enzymes, *Bam*HI, *Hind*III, *Eco*RI, *Not*I, *Pst*I, and *Eag*I were from Boehringer Mannheim, and *Bss*HII was from New England Biolabs. PCR was performed by using Ampli *Taq* polymerase from Perkin–Elmer. Isopropyl β -D-thiogalactopyranoside and 5-bromo-4-chloro-3-indolyl β -D-galactoside were purchased from GIBCO/BRL. Digoxigenin-11-dUTP (Dig-11-dUTP), anti-digoxigenin-alkaline phosphatase conjugate, 5-bromo-4-chloro-3-indolyl phosphate, and nitroblue tetrazolium salt were from Boehringer Mannheim. Vent DNA polymerase was from New England Biolabs. Oligonucleotide primers for PCR and DNA sequencing were synthesized on automated instruments from Applied Biosystems (Biopolymers Core DNA Synthesis, University of Michigan). BCA and Bradford reagent were from Pierce.

PCR and Probe Labeling. PCR was performed with a Perkin–Elmer Cetus GeneAmp PCR system 9600. The reaction conditions were as follows: primers (each at 1 μ M), P-MA1 DNA (0.3 μ g), dNTPs (each at 200 μ M), MgCl₂ (2 mM) in 10 mM Tris-HCl, 50 mM KCl, pH 8.3 (total reaction volume 100 μ l). The reaction was started by adding 2.5 units of *Taq* polymerase in the reaction mixture at 95°C. Cycling parameters were as follows (for 30 cycles): denaturing at 95°C for 45 sec, annealing at 50°C for 1 min, extending at 72°C for 90 sec. For probe labeling reactions, where we wanted to incorporate Dig-11-dUTP instead of dTTP in the PCR product, the conditions for PCR were the same as above except a mixture of 130 μ M dTTP and 200 μ M Dig-11-dUTP was used instead of 200 μ M dTTP. All PCR products were purified by

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.

© 1997 by The National Academy of Sciences 0027-8424/97/947233-6\$2.00/0
PNAS is available online at <http://www.pnas.org>.

Abbreviations: MHPCO, 2-methyl-3-hydroxypyridine-5-carboxylic acid oxygenase; P-MA1, *Pseudomonas* sp. MA-1; Dig-11-dUTP, digoxigenin-11-dUTP; PHBH, *p*-hydroxybenzoate hydroxylase. Data deposition: The sequence reported in this paper has been deposited in the GenBank database (accession no. AF001965). *To whom reprint requests should be addressed. e-mail: massey@umich.edu.

using QIAquick-spin columns (Qiagen). The concentration of Dig-11-dUTP-labeled probe was quantified according to methods described in the Boehringer Mannheim Genius system user's guide, version 3.0 (7).

Library Screening and Gene Cloning. The general procedures for library screening and gene cloning were carried out as described in ref. 8. P-MA1 DNA was partially purified to isolate a fraction that contains a high concentration of the MHPCO gene. Briefly, genomic P-MA1 DNA was digested with *Pst*I and run on 0.5% agarose gel. The digested DNA was transferred from the gel to a nylon membrane by the turbo-blotter transfer system (Schleicher & Schuell). The membrane was hybridized with Dig-11-dUTP labeling probe (probe concentration 20 ng/ml) according to the method described in ref. 7. Hybridization and the final wash were performed at 65–68°C. The probe was hybridized with a 3.5-kb fragment of DNA. The *Pst*I-cut DNA near this 3.5-kb region was isolated from agarose gel by using a QIAquick-spin column.

P-MA1 DNA from the above procedure was ligated to the *Pst*I site of pBluescriptII SK(+) and transformed to *E. coli* JM109. White colonies, which contain the DNA insert in the cloning vector, were subjected to the *in situ* hybridization procedure as described in detail in ref. 7.

DNA Sequencing. PCR products and genomic DNA fragments were sequenced with an Applied Biosystems DNA Sequencer model 373A using the PRISM Ready Reaction Dye Deoxy Terminator Sequencing Kit (DNA Sequencing Core Facility, University of Michigan). T7 and SP6 primers were used to sequence the PCR product. T7, T3, and sequence specific primers were used to sequence both strands of the genomic DNA fragment. The Wisconsin Sequence Analysis package (Genetics Computer Group, Madison, WI) version 8.1 was used for sequence analysis.

N-Terminal and Internal Sequence of MHPCO. N-terminal protein sequence analysis by automated Edman degradation was performed using standard procedures on a pulse liquid phase sequenator (Applied Biosystems model 473). Internal sequence information was obtained from N-terminal sequencing of an isolated fragment of MHPCO after cyanogen bromide cleavage. Both N-terminal and internal sequence analysis of MHPCO were done by the Protein and Carbohydrate Structure Core Facility, University of Michigan.

Steady-State Kinetics. MHPCO assay reaction progress was monitored at 340 nm using $\Delta \epsilon_{340} = 7.03 \text{ mM}^{-1}\cdot\text{cm}^{-1}$ ($\Delta \epsilon_{340}$ of NADH = 6.22; $\Delta \epsilon_{340}$ of 5-hydroxynicotinic acid = 0.81 $\text{mM}^{-1}\cdot\text{cm}^{-1}$). Initial rate measurements were made at 25°C, 50 mM sodium phosphate, pH 8.0, using the stopped-flow spectrophotometer (Hi-Tech Scientific SF-61), similar to the method described in ref. 9. One reaction syringe of the stopped-flow spectrophotometer contained an anaerobic solution of MHPCO (0.7 μM). The other reaction syringe contained appropriate concentrations of NADH, 5-hydroxynicotinic acid, and oxygen. The concentration of oxygen in the substrate syringe was achieved by equilibration of the solution with standardized oxygen/nitrogen mixtures. A minimum of three or four estimations were performed at each concentration of substrate.

RESULTS

N-Terminal and Internal Sequence of MHPCO and Synthesis of DNA Probe. The N-terminal sequence (residues 1–30) of MHPCO was determined to be ANVNKTPGKARRAE-VAGGGFAGLTAAIALK. The sequence of 14 residues of the internal fragment obtained by cyanogen bromide cleavage was determined to be HNKSVLKETFNGLP. From this sequence information, two degeneracy primers were designed to use in PCR to amplify the DNA fragment flanking both amino acid sequences. The first primer, designed to account for residues 2–10 (NVNKTGKA) of the N-terminal sequence,

had the following 5' to 3' sequence: (T/C)GTIAA(T/C)-AA(A/G) ACICIGG(A/T/G/C)AA(A/G) GC. The second primer (antisense strand), designed to account for sequence HNKSVLKE of the internal sequence, had the following 5' to 3' sequence: TC(T/C)TTIA(G/A)IACI(G/C)-(T/A)(T/C)TT(A/G) TT(A/G)TG.

PCR procedures using both primers and the reaction conditions as described in *Materials and Methods* resulted in a DNA product of 270 nucleotides. This PCR product was purified from agarose gel and ligated to a pGEM-T vector. *E. coli* JM109 was used as a host for transformation of this PCR product-inserted plasmid. Sequencing showed that the PCR product had a nucleotide sequence consistent with the N-terminal 30 amino acid at one end and the internal sequence of HNKSVLKE at the other end, confirming that this PCR product is the N-terminal part of the MHPCO gene. We then used this PCR product as a template for generating the probe for library screening as described in *Materials and Methods*.

Library Screening and DNA Mapping. The partial P-MA1 DNA library constructed as described in *Materials and Methods* was screened with the 270-nt probe by the colony hybridization procedure as described in ref. 7. One colony of the total of 150 colonies showed a strong positive signal with the probe, implying that that colony contained the insert that has the MHPCO gene.

The plasmid (pBluMH) from the positive colonies was purified and mapped to locate the position of the probe in the insert. The plasmid was digested separately with *Eag*I and *Bss*HIII, restriction enzymes that each would cut the probe sequence at only one site (Fig. 1). The plasmid also was double-digested with *Eag*I + *Pst*I, and *Bss*HIII + *Pst*I. The digested plasmid then was run on 0.8% agarose gel and Southern-hybridized with the probe. The results are shown in Fig. 2.

In Fig. 2A, lane 3, *Eag*I-digested pBluMH results in 4.5-, 1.1-, 0.4-, and 0.2-kb fragments (the last two fragments are very faint). Because pBluescript vector has a size of 3 kb and has only one restriction site for *Eag*I, which is close to the T3 promoter, the finding of a 4.5-kb fragment implies that the *Eag*I sites responsible for this 4.5-kb fragment are the *Eag*I site of pBluescript and the site located approximately midway between the *Pst*I sites of T7 and T3 (i.e., about 1.5 kb from the *Pst*I cutting site near T7 promoter) (see Fig. 3). From Southern hybridization (Fig. 2B, lane 4) results of pBluMH digested with *Eag*I, we can see that the probe hybridizes to the fragments of 0.2 kb and 1.1 kb, implying that these two fragments contained the probe sequence and were next to each other in the pBluMH map. Because the signal is more intense in the 1.1-kb fragment than in the 0.2-kb fragment, it implied that the 0.2-kb contains the sequence of 5' side of the probe (66 nucleotides) and the 1.1-kb fragment contains the sequence of 3' region of the probe (204 nucleotides) as illustrated in Fig. 3A. In Fig. 2A, lane 5, pBluMH that has been double-digested with *Eag*I + *Pst*I resulted in 3.0-, 1.6-, 1.1-, 0.4-, and 0.2-kb fragments and also two light bands of 2.0 and 1.3 kb resulting from incomplete digestion, implying that the 0.4-kb fragment is next to the 1.6-kb fragment in the pBluMH map. From the Southern hybridization (Fig. 2B, lane 2), the incomplete digestion fragment of 0.6 kb also was observed, implying that the 0.2-kb fragment is next to the 0.4-kb fragment in pBluMH map. The results from this *Eag*I + *Pst*I double-digestion and the results




FIG. 1. Location of restriction enzyme *Eag*I and *Bss*HIII sites in the probe sequence. The *Eag*I site is located 66 nucleotides and *Bss*HIII site is located 192 nucleotides from the 5' end. The mark indicates the length representing 75 nucleotides.




FIG. 2. DNA mapping of pBluMH. (A) Molecular mass markers (lanes 1 and 7). pBluMH digested with *PstI* (lane 2), *EagI* (lane 3), *BssHIII* (lane 4), *EagI* + *PstI* (lane 5), and *BssHIII* + *PstI* (lane 6). (B) Southern hybridization of the gel in A. pBluMH digested with *BssHIII* + *PstI* (lane 1), *EagI* + *PstI* (lane 2), *BssHIII* (lane 3), *EagI* (lane 4), *PstI* (lane 5), and DNA molecular mass markers (lane 6).

obtained from *EagI* digestion suggested that the probe region was located about 1.3 kb from the T3 promoter side with the orientation shown in Fig. 3A.

In Fig. 2A, lane 4, pBluMH digested with *BssHIII* resulted in 2.9-, 1.15-, 1.4-, 0.5-, 0.3-, and 0.3-kb fragments with those of 1.1 and 0.5 kb containing the probe as shown by the Southern hybridization results (Fig. 2B, lane 3), implying that the probe region is located in these 1.1- and 0.5-kb fragments. Because the signal of 0.5-kb fragment is more intense than that of the 1.1-kb fragment, it implied that the 0.5-kb fragment contains the 5' side of the probe (192 nucleotides), and the 1.1-kb fragment contains the 3' side (78 nucleotides). According to the pBluescript map, we would expect to see the DNA fragment next to the pBluescript vector at the T3 promoter site in pBluMH to be about 0.1 kb smaller when double-digested with *BssHIII* + *PstI* than when digested with *BssHIII* alone. The




FIG. 3. Construction of pPC1 expression plasmid. (A) Plasmid pBluMH. The thin line indicates the plasmid region derived from pBluescript vector, the empty box indicates the probe area. Number in parenthesis indicates the length of DNA (in kb) with reference to the *PstI* site near T3 promoter as the origin point. MHPCO gene (B) was isolated from pBluMH by PCR and ligated to pET-11a (C), resulting in the expression plasmid pPC1 (D). The mark indicates the length representing 1,000 nucleotides.

Southern hybridization results show that the 1.1-kb fragment from *BssHIII* digestion corresponds to a 1-kb fragment in the *BssHIII* + *PstI* double-digestion. Therefore, the probe region should be located about 1.3 kb from the T3 promoter, as shown in Fig. 3A, in good agreement with the results obtained from the *EagI* and *EagI* + *PstI* digestions.

Nucleotide Sequencing Analysis. pBluMH is sequenced in both strands. The nucleotide sequence and the derived primary structure of MHPCO are presented in Fig. 4. Residues 2–31 of the deduced protein sequence corresponded to the N-terminal sequence of purified MHPCO. The ORF predicts a 379-aa protein with a calculated molecular mass of 41.7 kDa, consistent with the subunit molecular mass of MHPCO determined by SDS/PAGE. Therefore, the entire MHPCO gene was located in pBluMH as illustrated in Fig. 3A.

MHPCO Expression. The MHPCO gene was isolated from pBluMH by using PCR with proofreading DNA polymerase (Vent DNA polymerase). Two primers with the following 5' to 3' sequence: AGGATAGCATATGGCCAATGTAAA (sense strand) and CTTCTGCGGATCCAATTGATCTGT (anti-sense strand) were used to amplify the MHPCO gene, and at the same time introduce the restriction sites for *NdeI* and *BamHI* at the beginning and the end of the gene. The MHPCO gene from the PCR reaction was isolated from agarose gel and digested with *NdeI* and *BamHI*.

The expression plasmid pPC1 was constructed by digesting the expression vector pET-11a with *NdeI* and *BamHI* and ligating with *NdeI* and *BamHI* double-digested MHPCO gene. The plasmid pPC1 was transformed into JM109 for amplification. Plasmid DNA was isolated and sequenced, showing that pPC1 contained the correct MHPCO gene sequence without any error introduced by PCR. pPC1 then was transformed to the expression host, BL21(DE3). The construction of the expression plasmid is summarized as in Fig. 3.

Protein Purification. BL21(DE3) that contained pPC1 plasmid was grown in Luria–Bertani media plus ampicillin (50 $\mu\text{g/ml}$) at 37°C. When OD₆₀₀ of cells was about 0.8, the culture was cooled to 23°C, and 1 mM isopropyl β -D-thiogalactopyranoside was added to induce protein expression. Cells were allowed to grow at this temperature until OD₆₀₀ reached about 4.5. The cells were sonicated and centrifuged. The supernatant was assayed and found to have MHPCO activity. BL21(DE3) without the plasmid pPC1 also was grown as a control. The control cells do not contain any MHPCO activity.

MHPCO from the induced *E. coli* was purified according to the method described in ref. 4. About 50 mg of pure MHPCO was obtained from 10 L of cell culture (43 g of cell paste). The recombinant MHPCO shows the same visible spectrum as does P-MA1 MHPCO, with wavelength maxima of 382, 454 nm. Both enzymes have the same specific activity under the assay conditions.

Stoichiometry of FAD/Subunit. The amount of FAD in cloned and P-MA1 MHPCO solution was quantified by using the determined ϵ_{454} of 13.11 $\text{mM}^{-1}\text{cm}^{-1}$ (1). The amount of protein was quantified by both the bicinchoninic acid (BCA) method (10) and the Coomassie dye binding (Bradford) method (11). The enzyme used in this procedure was in buffer without DTT to eliminate interference of DTT with the BCA method. BSA was used as a standard to quantify the amount of protein. Because protein assays are known to have protein-to-protein variability, we also used *p*-hydroxybenzoate hydroxylase (PHBH) as another standard. The stoichiometry of FAD/subunit was calculated in both cloned and P-MA1 MHPCO. The results are shown in Table 1.

The results in Table 1 show that both cloned and P-MA1 MHPCO have 1 FAD/subunit. Because MHPCO is a tetrameric protein (1, 6), the enzyme has four FAD/tetramers. This result differs from that of Sparrow *et al.* (1), who reported that MHPCO has two FAD/tetramers. Because only a single gene product of 42 kDa is encoded, it can be concluded that

GTCGCCCTCGGCCATGGCCAGACCCGCAAGGGTCTGCCGCGAGACCTGACACAGGCCATCGGGACGTGACGAAACCCGTGCTCATCGTTNGCGGCAACAAGCAAGC 110
 TGGTTTCCCGCGCGCGCTGGCAAAAGCAGCGCGGCTGCCGCGGACCTGCCGTTGGTGTGTCGTCCTGACGCTGACCACTACGTCACAGAGACGGCTCCCGAGATCACG 220
 CTGAAAGCCATCACCAATTTTCATCGACGCGCTGACGGCCGCAACACGCCGCTGCGCTTGTATGCAGGATCAGGATAGAAAATGGCCAAATGTAACAAAACTCCGGGCAAGG 330
 Met Ala Asn Val Asn Lys Thr Pro Gly Lys
 CGCTGCTGCCGAGTGCCTGGTGGCGGCTTTGCCGCGCTGACGGCCGATAGCGTGAAGCAGAGCGGTTGGATGTCAGGCTGCAGAAAAGAGTTCGAGCTCCGG 440
 Ala Arg Arg Ala Glu Val Ala Gly Gly Gly Phe Ala Gly Leu Thr Ala Ala Ile Ala Leu Lys Gin Ser Gly Trp Asp Val Arg Leu His Glu Lys Ser Ser Glu Leu Arg
 GCTTTCCGGTGTGGCATCTATCTCTGGCACAACGGCTTCCGCTCCTCGAAGGGCTGGGCGCGCTGGACGATGTTCTGCAAGGCTCCACACGCCCGACCTATGAAAC 550
 Ala Phe Gly Ala Gly Ile Tyr Leu Trp His Asn Gly Leu Arg Val Leu Glu Gly Leu Gly Ala Leu Asp Asp Val Leu Glu Gly Ser His Thr Pro Pro Thr Tyr Glu Thr
 CTGGATGCACAACAAGTCCGTTTCCAAGGAAACGTTCAACGGTCTGCCCTGGCGCATCATGACCCGACGCCATCTGCACGATGCGCTTGTCAACCGCGCCGCTGCGCTGG 660
 Trp Met His Asn Lys Ser Val Ser Lys Glu Thr Phe Asn Gly Leu Pro Trp Arg Ile Met Thr Arg Ser His Leu His Asp Ala Leu Val Asn Arg Ala Arg Ala Leu
 GGATCGACATCCGCGTCAATTCGAAGCGGTGCTGCCGATCCGGAAGCGGCTGACCTTGAGAGCGGTGAAGTTCTCGAAGCCGACCTGATCGTGGTGGCGACGGC 770
 Gly Ile Asp Ile Arg Val Asn Ser Glu Ala Val Ala Ala Asp Pro Glu Gly Arg Leu Thr Leu Glu Ser Gly Glu Val Leu Glu Ala Asp Leu Ile Val Gly Ala Asp Gly
 GTCGGCTCAAGGTCAGGGATTCATCGGCTTCAAGCAGGATCGATGGATTTCAAGGACGGGCTCATCCGGCTGATCGTCCCGCGCATGAAGAAGGAACCTCGGTCTATGG 880
 Val Gly Ser Lys Val Arg Asp Ser Ile Gly Phe Lys Glu Asp Arg Trp Ile Ser Lys Asp Gly Leu Ile Arg Leu Ile Val Pro Arg Met Lys Lys Glu Leu Gly His Gly
 CGAGTGGGACAACACCATCGACATGTGGAACCTTCTGCCGCGCGCTCCAGCGCATCTCTATTCGCCCTGCAATGAGAACGAGCTCTATCTCGGTCTGATGGTCCAGCCG 990
 Glu Trp Asp Asn Thr Ile Asp Met Trp Asn Phe Trp Pro Arg Val Glu Arg Ile Leu Tyr Ser Pro Cys Asn Glu Asn Glu Leu Tyr Leu Gly Leu Met Ala Pro Ala
 CCGATCCGCGCGGATCGGCAGTCCCGATCGATCTCGAGGTCTGGTTCGAGATGTTCCCTTCCTGGAGCCGTCCTGGTTCGAGGGCGCAAGCTTAAACCCGCCGGTAC 1100
 Ala Asp Pro Arg Gly Ser Ala Val Pro Ile Asp Leu Glu Val Trp Val Glu Met Phe Pro Phe Leu Glu Pro Cys Leu Val Glu Ala Ala Lys Leu Lys Thr Ala Arg Tyr
 GACAAATACGAGACGACCAAGCTGGACAGCTGGACACGAGGCAAGGTCGCCCTTGTGGCGATGCCCGCACGCAATGTCGCCGCGCTCGCGCAGGGCGCGGTTGCGC 1210
 Asp Lys Tyr Glu Thr Thr Lys Leu Asp Ser Trp Thr Arg Gly Lys Val Ala Leu Val Gly Asp Ala Ala His Ala Met Cys Pro Ala Leu Ala Glu Gly Ala Gly Cys Ala
 GATGGTCAATGCCTTCAGCCCTCGCAGGACCTGGAGGCGGGCTCTCCGTCGAGGACGCACTCGTCGATTGGGAGAAGCGCATTGCCCCGATCACCGATCGCTGCCAGG 1320
 Met Val Asn Ala Phe Ser Leu Ser Glu Asp Leu Glu Ala Gly Ser Ser Val Glu Asp Ala Leu Val Asp Trp Glu Lys Arg Ile Arg Pro Ile Thr Asp Arg Cys Glu
 CACTGTCTGGCGAGTACGCCGCAACCGTCTCGCTCTCGAACGGCAACATGTTACGCGCGGACGCCCTGGAAGCAGCGGTTACGATCCGCTGCGCGGTCTTTTCATGG 1430
 Ala Leu Ser Gly Gly Tyr Ala Ala Asn Arg Ser Leu Ser Asn Gly Asn Met Phe Thr Pro Ala Ala Leu Glu Ala Ala Arg Tyr Asp Pro Leu Arg Arg Val Phe Ser Trp
 CCGCAATAATCTCGAACGGCGGTCAACAGATCAATTGGTGGCGCAGAAGCTGTGCTCTCCCGAGGATGAAGATGGAATATTC 1515
 Pro Glu •

FIG. 4. Nucleotide sequence of MHPCO gene, including upstream and downstream flanking regions and the predicted MHPCO sequence.

the enzyme has an α_4 structure, not an $\alpha_2\beta_2$ structure as suggested by Kishore *et al.* (6).

Table 1 shows that BSA can be used as a protein standard for protein assays for both MHPCO and PHBH, because the protein quantitation using BSA as a standard gives the same result as when PHBH is used as a standard.

Steady-State Kinetics. A general equation that describes the steady-state kinetics of MHPCO is shown in Eq. 2 (4, 5, 12, 13).

$$e/v = \phi_0 + \phi_A/[A] + \phi_B/[B] + \phi_C/[C] + \phi_{AB}/[A][B]. \quad [2]$$

The steady-state parameters, k_{cat} and K_m values for 5-hydroxynicotinic acid, NADH, and O_2 , were derived from the values of $1/\phi_0$, ϕ_A/ϕ_0 , ϕ_B/ϕ_0 , ϕ_C/ϕ_0 , respectively. The values of ϕ_0 , ϕ_A , ϕ_B , and ϕ_C were evaluated according to the graphical method described in ref. 12. The kinetic constants K_m of cloned and P-MA1 MHPCO are summarized in Table 2. K_m values of cloned and P-MA1 are all similar within the experimental uncertainty, implying that the recombinant MHPCO has the same properties as the native MHPCO from P-MA1. Cloned MHPCO has k_{cat} value of 552 min^{-1} . P-MA1 MHPCO is assumed to have the same k_{cat} value as in cloned MHPCO,

Table 1. The amount of FAD per subunit

Type of MHPCO	Method used		
	BCA (BSA as a standard)	BCA (PHBH as a standard)	Bradford (BSA as a standard)
Cloned	1.0 ± 0.1	0.94 ± 0.06	0.93 ± 0.04
P-MA1	1.03 ± 0.03	—	1.03 ± 0.03

because both enzymes have the same specific activity under the assay conditions (4).

Homology with Other Hydroxylases. The amino acid sequence comparison between MHPCO and other flavoprotein hydroxylases [PHBH (14, 15), phenol hydroxylase (16), salicylate hydroxylase (17), 2–4-dichlorophenol hydroxylase (18), pentachlorophenol hydroxylase (19), and 4-aminobenzoate hydroxylase (20)] shows that three amino acid sequence regions are very conserved among these hydroxylases (Fig. 5). The first region (region A; residues 18–34 in MHPCO) is a consensus sequence associated with an ADP binding site. This ADP binding fingerprint forms a characteristic secondary structure, called a $\beta\alpha\beta$ -fold or Rossmann fold (21, 22). In PHBH, this region is a binding site for the ADP portion of FAD (23).

The second region (region B; residues 154–160 in MHPCO) is very conserved among the aromatic flavoprotein hydroxylases. The third conserved region (region C; residues 281–295 in MHPCO) contains the first part of a sequence that was reported as a fingerprint for the binding site of the ribityl moiety of FAD (24) (region C1; the underlined sequence). However, the second part of the third conserved region (region

Table 2. K_m values, μM

Type of MHPCO	5HN	NADH	O_2
Cloned	65 ± 5	180 ± 22	148 ± 33
P-MA1	68 ± 16	205 ± 20	126 ± 27

5HN, 5-hydroxynicotinic acid.




FIG. 5. Alignment of MHPCO with other aromatic flavoprotein hydroxylases. Black areas indicate amino acid residues conserved in all six hydroxylases, and the gray boxes indicate amino acid residues conserved in two or more hydroxylases. (A) Conserved region A: residues 18–34 in MHPCO or 9–21 in PHBH. (B) Conserved region B: residues 154–157 in MHPCO, residues 157–160 in PHBH. (C) Conserved region C: residues 281–295 in MHPCO or residues 279–293 in PHBH. The underlined sequence is the conserved region C1, and the nonunderlined sequence is the conserved region C2.

C2) has not previously been included as a fingerprint for an FAD binding region.

When the SwissProt and Genpept protein databases were scanned using the conserved region B and C with space between 10–300 residues, only aromatic flavoprotein hydroxylases and putative FAD-binding proteins were extracted (Table 3). We examined the derived sequences of these unknown proteins and found that two of them have all three conserved regions A–C as in aromatic flavoprotein hydroxylases. The protein with accession code U29897 lacking N-terminal sequence data contains the conserved regions B and C. It is possible that the region A is in the lacking N-terminal sequence. It is possible that these hypothetical proteins are also aromatic flavoprotein hydroxylases.

DISCUSSION

This study reports the gene cloning, sequence determination, and enzyme expression of MHPCO, a flavoprotein monooxygenase.

Table 3. Proteins extracted from SwissProt and Genpept Database using sequence G-[AC]-D-G-X-X-[SG]-X(10-300)-G-X(5)-D-A-X-H

Proteins	
Known	
PHBH	
Phenol hydroxylase	
Salicylate hydroxylase	
2,4-Dichlorophenol hydroxylase	
Pentachlorophenol hydroxylase	
4-Aminobenzoate hydroxylase	
Hypothetical	
52.4 kDa protein in ATP-ROX3, intergenic region (GenBank accession code P38169)	
Partial sequence of FAD binding gene (GenBank accession code U29897)	
Putative oxygenase from biosynthesis and oxygenation pathway of urdamycin A (GenBank accession code X87093)	

Database searching used the PatternFind server from the Bioinformatics Group at the Swiss Institute for Experimental Cancer Research (<http://ulrec3.unil.ch:80/software>).

Characterization of the cloned enzyme clearly shows that all the properties of the enzyme so far examined are the same as those of the native enzyme from P-MA1. These properties include the subunit molecular mass, specific activities with MHPC and 5-hydroxynicotinic acid, K_m for each substrate, and stoichiometry of FAD/subunit. Because MHPCO is a tetrameric protein and the cloned MHPCO was expressed as a single polypeptide of 379 amino acids, it clearly demonstrates that MHPCO is a homotetrameric protein with one flavin bound to each subunit.

Sequence comparison of MHPCO with PHBH shows that the two enzymes have about 26% identity. The identity between PHBH with individual enzymes in the flavoprotein hydroxylase class [phenol hydroxylase (16), salicylate hydroxylase (17), 2,4-dichlorophenol hydroxylase (18), pentachlorophenol hydroxylase (19), and 4-aminobenzoate hydroxylase (20)] is 23–33%. With this level of identity, it may be assumed that all of the flavoprotein hydroxylases have a similar core structure (25). Currently, the only enzyme in the class where the three-dimensional structure is known is PHBH (26).

From all the proteins listed in the SwissProt and Genpept protein databases, the only proteins that have all of the three conserved regions shown in Fig. 5 are the flavoprotein hydroxylases themselves and the hypothetical proteins where only DNA sequences were identified (Table 3). These hypothetical proteins have lengths of 460, 495, and >287 amino acid residues, and thus are in the range of the known aromatic flavoprotein hydroxylases, which all have molecular mass of 40–55 kDa per subunit. It is likely that these hypothetical proteins are also aromatic flavoprotein hydroxylases.

These highly conserved amino acid sequences in aromatic flavoprotein hydroxylases may have some importance in the catalytic functions of the enzymes. Region A, residues 18–34 in MHPCO or 9–21 in PHBH, is clearly involved in the binding of the ADP moiety of FAD (23–24), as shown by its sequence and location in PHBH. Region C1, residues 281–288 in MHPCO or residues 279–286 in PHBH, was proposed to be a fingerprint for the binding of FAD (24). However, region C2 (residues 289–295 in MHPCO or residues 287–293 in PHBH), which is not included in the fingerprint proposed by Eggink *et al.* (24), is very conserved among the aromatic flavoprotein hydroxylases, but not in other flavoproteins. In the PHBH structure, the location of this sequence is in the loop close to the protein surface and also close to the region B (residues 154–157 in MHPCO, residues 157–160 in PHBH). It can be envisaged that these two regions may have importance in enzyme function.

One of the common properties among the aromatic flavoprotein hydroxylases is that the enzymes require three substrates: aromatic substrate, NAD(P)H, and O₂. It is known that the hydroxylation reaction takes place in the catalytic pocket, which is the binding site for the aromatic substrate, the isoalloxazine ring of FAD, O₂, and the nicotinamide ring of NADPH. However, it is not known where the AMP moiety of the pyridine nucleotide binds to the enzyme. Because there is space between the catalytic pocket and the loops of regions B and C, it is possible that the area around these two loops is the recognition site for the AMP moiety of pyridine nucleotide. To test this possibility, we modeled the NADPH molecule into PHBH in a way that the nicotinamide ring was almost parallel to the isoalloxazine ring of the flavin so that the hydride equivalent can be transferred from the pro-R side of the nicotinamide ring to the *re*-side of the flavin (27), and also similar to the arrangement described in ref. 28. With this configuration, it is possible to have the AMP moiety of NADPH docking around the loop of 287–289, region C2 (Fig. 6), which is near to region B.

The information obtained so far cannot determine if the arrangement of Fig. 6 is correct. Wierenga *et al.* (28) proposed that the pyrophosphate group of NADPH can form salt bridges with R166, R269, or H162 in PHBH. R166 and H162 are located near the conserved region B. Suzuki *et al.* (29) reported




FIG. 6. The postulated model of binding of NADPH molecule in PHBH. FAD is indicated as the molecule on the left (line drawing), and NADPH is indicated as the molecule on the right (ball and stick drawing). The PHBH molecule is represented as gray ribbon. Residues 157–160 and 163 are indicated as the black loop on the left. Residues 287–289 and 293 are indicated as the black loop on the right.

that K165 in salicylate hydroxylase (corresponding to H162 in PHBH) is important for the binding of NADH as shown by chemical modification studies. This information is consistent with the mode of binding postulated in Fig. 6. However, Seibold *et al.* (30) suggest that helix H2 (residues 35–42) in PHBH is involved in the binding of pyridine nucleotide. This is based on the results of chemical modification studies that implicated Y38 in the binding of pyridine nucleotide and the result of sequence comparison between PHBH from *Pseudomonas fluorescens* and PHBH from *Pseudomonas* sp. CBS3 (30). PHBH from *P. fluorescens* uses NADPH as a substrate while PHBH from *Pseudomonas* sp. CBS3 uses NADH (30). The sequence difference between the two enzymes around helix H2 leads to the postulation that helix H2 is involved in determining the pyridine nucleotide specificity. It should be noted, however, that there are other regions besides helix H2 that differ in sequence. Clearly, this latter proposal is inconsistent with the model of NADPH binding of Fig. 6. Therefore, we cannot rule out the possibility that the second and third conserved regions are not involved in the binding of pyridine nucleotide, but rather are involved in some other role such as structural stabilization.

In conclusion, MHPCO has been cloned, sequenced, and expressed in *E. coli*. We have shown that the enzyme is a homotetrameric protein with one FAD per subunit. The sequence comparison of MHPCO and aromatic flavoprotein hydroxylases show several conserved sequence regions.

We thank Mr. Witoon Tirasophon and Dr. Betty Jo Brown for valuable suggestions during the gene cloning process. We thank Ms. Mariliz Ortiz-Maldonado for providing PHBH used for a standard on protein determination, and Dr. Brian Guenther for suggestions about

protein database searching. This work was supported by the U.S. Public Health Service, Grants GM 20877 (D.P.B.) and GM 11106 (V.M.), and the Development and Promotion of Science and Technology Talent Project, Thailand (P.C.).

- Sparrow, L. G., Ho, P. P. K., Sundaram, T. K., Zach, D., Nyns, E. J. & Snell, E. E. (1969) *J. Biol. Chem.* **244**, 2590–2600.
- Burg, R. W., Rodwell, V. W. & Snell, E. E. (1960) *J. Biol. Chem.* **235**, 1164–1169.
- Sundaram, T. K. & Snell, E. E. (1969) *J. Biol. Chem.* **244**, 2577–2585.
- Chaiyen, P., Brissette, P., Ballou, D. P. & Massey, V. (1997) *Biochemistry* **36**, 2612–2621.
- Chaiyen, P., Brissette, P., Ballou, D. P. & Massey, V. (1997) *Biochemistry*, in press.
- Kishore, G. M. & Snell, E. E. (1981) *J. Biol. Chem.* **256**, 4234–4240.
- Boehringer Mannheim Co. (1995) *Genius System User's Guide for Membrane Hybridization, Version 3.0*.
- Sambrook, J., Fritsch, E. F. & Maniatis T. (1989) *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Lab. Press, Plainview, NY).
- Husain, M. & Massey, V. (1979) *J. Biol. Chem.* **254**, 6657–6666.
- Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J. & Klenk, D. C. (1985) *Anal. Biochem.* **150**, 76–85.
- Bradford, M. M. (1976) *Anal. Biochem.* **72**, 248–254.
- Dalziel, K. (1969) *Biochem. J.* **114**, 547–556.
- Cleland, W. W. (1975) *Biochemistry* **14**, 3220–3224.
- Weijer, W. J., Hofsteenge, J., Beintema, J. J., Wierenga, R. K. & Drenth, J. (1983) *Eur. J. Biochem.* **133**, 109–118.
- Entsch, B., Nan, Y., Weaich, K. & Scott, K. F. (1988) *Gene* **71**, 279–291.
- Nurk, A., Kasak, L. & Kivisaar, M. (1991) *Gene* **102**, 13–18.
- You, I.-S., Ghosal, D. & Gunsalus, I. C. (1991) *Biochemistry* **30**, 1635–1641.
- Perkin, E. J., Gordon, M. P., Caceres, O. & Lurquin, P. F. (1990) *J. Bacteriol.* **172**, 2351–2359.
- Orser, C. S., Lange, C. C., Xun, L., Zahrt, T. C. & Schneider, B. J. (1993) *J. Bacteriol.* **175**, 411–416.
- Tsuji, H., Oka, T., Kimoto, M., Hong, Y. M., Natori, Y. & Ogawa, T. (1996) *Biochim. Biophys. Acta.* **1309**, 31–36.
- Rossmann, M. G., Moras, D. & Olsen, K. W. (1974) *Nature (London)* **250**, 194–199.
- Wierenga, R. K., Terpstra, P. & Hol, W. G. J. (1986) *J. Mol. Biol.* **187**, 101–107.
- Wierenga, R. K., Drenth, J. & Schulz, G. E. (1983) *J. Mol. Biol.* **167**, 725–739.
- Eggink, G., Engel, H., Vriend, G., Terpstra, P. & Witholt, B. (1990) *J. Mol. Biol.* **212**, 135–142.
- Sander, C. & Schneider, R. (1991) *Proteins Struct. Funct. Genet.* **9**, 56–68.
- Wierenga, R. K., de Jong, R. J., Kalk, K. H., Hol, W. G. J. & Drenth, J. (1979) *J. Mol. Biol.* **131**, 55–73.
- Manstein, D. J., Pai, E. F., Schopfer, L. M. & Massey, V. (1986) *Biochemistry* **25**, 6807–6816.
- Wierenga, R. K., Kalk, K. H., van der Lann, J. M., Drenth, J., Hofsteenge, W. J. W., Jekel, P. A., Beintema, J. J., Muller, F. & van Berkel, W. J. H. (1982) in *Flavins and Flavoproteins*, eds. Massey, V. & Williams, C. H. (Elsevier/North-Holland, New York), pp. 11–18.
- Suzuki, K., Mizuguchi, M., Gomi, T. & Itagaki, E. (1995) *J. Biochem.* **117**, 579–585.
- Seibold, B., Matthes, M., Eppink, M. H. M., Lingens, F., Van Berkel, W. J. H. & Muller, R. (1996) *Eur. J. Biochem.* **239**, 469–478.